Abstract
Rapid large-scale testing is essential for controlling the ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The standard diagnostic pipeline for testing SARS-CoV-2 presence in patients with an ongoing infection is predominantly based on pharyngeal swabs, from which the viral RNA is extracted using commercial kits followed by reverse transcription and quantitative PCR detection. As a result of the large demand for testing, commercial RNA extraction kits may be limited and alternative, non-commercial protocols are needed. Here, we provide a magnetic bead RNA extraction protocol that is predominantly based on in-house made reagents and is performed in 96-well plates supporting large-scale testing. Magnetic bead RNA extraction was benchmarked against the commercial QIAcube extraction platform. Comparable viral RNA detection sensitivity and specificity were obtained by fluorescent and colorimetric RT-LAMP using N primers, as well as RT-qPCR using E gene primers showing that the here presented RNA extraction protocol can be combined with a variety of detection methods at high throughput. Importantly, the presented diagnostic workflow can be quickly set up in a laboratory without access to an automated pipetting robot.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by a research grant from the Chica and Heinz Schaller Foundation (Schaller Research Group Leader Programme) to PC, VLDT, SLW and AF; by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), project number 240245660 SFB 1129 to PC, SK, VLDT, DG and H-GK; and by the German Center for Infection Research (DZIF TTU HIV 04.815) to DG, H-GK and KB.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics statement: The presented work was done with the intention to support SARS-CoV-2 diagnostics and improve emergency preparedness and response for COVID-19. Pseudo-anonymized surplus material from samples that had been collected for clinical diagnostics of SARS-CoV-2, were used to establish and validate the protocol presented here. This work complies with the German Act concerning the Ethical Review of Research Involving Humans, permitting the use of patient samples collected to perform the testing in question, for development and improvement of diagnostic assays. Overside body: Etikkomission der medizinischen Fakultaet Heidelberg Alte Glockengiesserei 11/1 69115 Heidelberg Tel.: 06221 562646-0 Fax: 06221 562648-0 ethikkommission-I@med.uni-heidelberg.de
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available in the manuscript.
